Mark Wright
Psychiatry · Lexington, KYNPI 1154448991
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $506,919 of the $637,028 with a category attached, or 79.6%. 30 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 25.9% of the total. 2025 is the largest year on record at $160,591, 5.4 times the $29,678 reported in 2019. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,079 payments — averaging $590.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$165K
- Axsome Therapeutics, Inc.$129K
- Alkermes, Inc.$127K
- Teva Pharmaceuticals USA, Inc.$97K
- Tris Pharma Inc$50K
- Neurocrine Biosciences, Inc.$49K
- plus $20K from 24 others
What the payments were for
- Consulting fees$79,59312%
- Speaking & faculty fees$506,91980%
- Travel & lodging$29,5945%
- Food & beverage$20,1623%
- Education$7410%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 325 | $165,197 |
| Axsome Therapeutics, Inc. | 121 | $129,170 |
| Alkermes, Inc. | 121 | $126,590 |
| Teva Pharmaceuticals USA, Inc. | 92 | $96,651 |
| Tris Pharma Inc | 88 | $49,606 |
| Neurocrine Biosciences, Inc. | 53 | $49,461 |
| Noven Pharmaceuticals, Inc. | 6 | $8,163 |
| Ironshore Pharmaceuticals Inc. | 23 | $5,118 |
| Noven Therapeutics, LLC | 18 | $2,803 |
| Corium, LLC | 41 | $799 |
| Otsuka America Pharmaceutical, Inc. | 31 | $592 |
| Lundbeck LLC | 29 | $520 |
| Neos Therapeutics, LP | 28 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $377 |
| AbbVie(2 entities) | 21 | $338 |
| Bausch Health US, LLC | 18 | $304 |
| Johnson & Johnson | 11 | $276 |
| Sunovion Pharmaceuticals Inc. | 6 | $126 |
| Collegium Pharmaceutical, Inc. | 6 | $118 |
| E.r. Squibb & Sons, L.L.C. | 2 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Vertical Pharmaceuticals, LLC | 3 | $48 |
| Shire North American Group Inc | 3 | $40 |
| Neuronetics, Inc. | 2 | $29 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Sage Therapeutics, LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Pernix Therapeutics Holdings, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$501,432
- QELBREE$156,511
- Auvelity$128,059
- AUSTEDO$59,332
- INGREZZA$48,737
- Dyanavel XR$47,900
- Quillivant$43,191
- Quillichew ER$42,952
- Austedo XR$35,469
- Xelstrym$10,646
- Jornay PM 20mg capsules (Bottle of 100)$4,674
- SPRAVATO$123
- VRAYLAR$114
- REXULTI$111
How this compares
$637,028 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 14 | $169,763 |
| AustedoDeutetrabenazine | 13 | $92,679 |
| RexultiBrexpiprazole | 18 | $38,780 |
| Wellbutrin XlBupropion Hcl | 14 | $33,415 |
| TrintellixVortioxetine Hydrobromide | 15 | $16,067 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 16 | $14,920 |
| LamictalLamotrigine | 15 | $10,063 |
| Bupropion XlBupropion Hcl | 247 | $6,421 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 95 | $6,132 |
| Duloxetine Hcl | 188 | $5,149 |
| Olanzapine | 55 | $4,140 |
| Buspirone Hcl | 146 | $3,711 |
| Vilazodone Hcl | 33 | $2,929 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 54 | $2,281 |
| Dextroamphetamine Sulfate | 16 | $1,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $96,651 | $262,44227 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $592 | $38,78018 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $377 | $16,06715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Lexington
- Steven CroleyLexington$151K
- Jacob BishopLexington$56K
- Andrew CooleyLexington$47K
- Syed RizviLexington$17K
- Michelle LofwallLexington$11K
- Saeed HamidLexington$10K
- Getulio TovarLexington$5K
- Brian KeltyLexington$4K
- Andre FernandezLexington$4K
- Carmen PintoElizabethtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.